Home » Health » Brazilian study on Sinovac vaccine affirms that effectiveness in preventing symptomatic infections rises to 62.3% when two doses are applied more than 21 days apart

Brazilian study on Sinovac vaccine affirms that effectiveness in preventing symptomatic infections rises to 62.3% when two doses are applied more than 21 days apart

This Sunday was a news day for the Sinovac vaccine. In the morning he found himself in the midst of general attention after the statements of the head of China’s disease control agency stating that vaccines from that country “do not have very high protection rates” in terms of avoiding contagion, which was later corrected by the same official, although he recognized that reinforcement strategies are being studied.

But good news came in the afternoon. And it was from Brazil, one of the countries in which clinical studies of the vaccine have been developed. This is because the Butantan Institute, which produces the vaccine in conjunction with China, revealed that New analyzes suggest that the inoculation scheme could be up to ten points more effective than what had been initially indicated, with a methodological change that has been applied in Chile since the beginning of the vaccination process.

This is because, although the study confirmed that the effectiveness of Coronavac – the Sinovac vaccine – to prevent symptomatic infections would reach 50.7%, this would be done through the application scheme that was suggested at the beginning: two doses separated by 14 days away.

However, The Butantan Institute assured that when the distance between doses was greater than 21 days, this effectiveness could go up to 62.3%. In the Chilean case, the process with Sinovac has always been in this range, since two doses are applied 28 days apart.

The effectiveness to prevent moderate cases of the disease, meanwhile, would reach 83.7%, not registering serious cases or deaths in the study group.

Even the news could be more auspicious. Speaking to O Globo, the head of the Phase 3 clinical study in Brazil, Ricardo Palacios, indicated that according to his studies, there are strong indications that the Sinovac vaccine would have a very similar protective behavior against the dreaded P1 variant initially detected in Brazil.

“What we expected is that, being a complete inactivated virus vaccine, it would have a greater resistance to losses of neutralization against variants and this was confirmed by the laboratory data: indeed both the P1 and P2 strains are neutralized in a similar way as It is the classic variant, ”said Palacios.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.